Fierce Pharma41m
J&J advances Stelara succession scheme with key FDA nod for Tremfya in Crohn's disease
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
Fierce Pharma57m
Alnylam's Amvuttra wins key approval in ATTR-CM, teeing up showdown with Pfizer
Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...
The Manila Times1h
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one ...
US FDA expands approval for Alnylam's drug to treat rare heart disease
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
Alnylam wins FDA approval for rare heart disease drug
Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major milestone — finally reaching profitability.
Alnylam's Amvuttra Gets Approval for Expanded Indication From FDA
Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.
Researchers find clue to delay Alzheimer's symptoms. Now they have to prove it
An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in ...
BioPharma Dive2h
Alnylam drug gets long-awaited FDA approval in deadly heart disease
Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...
US FDA Approves Alnylam's Drug for Rare Heart Condition
(Reuters) -U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, ...
MedPage Today4h
Preventive Care Mandate at Risk? More AI Wins in Cancer; Risky Short-Term Insurance
The American Medical Association and more than two dozen other health organizations joined in an amicus brief encouraging the ...
Opposing Sides Both See Victory in Pa. High Court Ruling on CBD Treatments Covered by Workers' Comp
The justices determined that the Workers’ Compensation Act requires employers to pay for any item used to treat an employee's ...
Abeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations
Q4 2024 Management View CEO Vish Seshadri highlighted the upcoming FDA decision on prademagene zamikeracel (pz-cel), scheduled for April 29, 2025, as a pivotal milestone. The company is preparing for ...